Get the Stockscreener App
1.785
0.83%
-0.015
After Hours:
1.79
0.005
+0.28%
Adlai Nortye Ltd Adr stock is traded at $1.785, with a volume of 7,097.
It is down -0.83% in the last 24 hours and up +15.16% over the past month.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
See More
Previous Close:
$1.80
Open:
$1.79
24h Volume:
7,097
Relative Volume:
0.88
Market Cap:
$55.76M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-0.7084
EPS:
-2.5197
Net Cash Flow:
-
1W Performance:
+2.00%
1M Performance:
+15.16%
6M Performance:
-23.72%
1Y Performance:
-8.93%
1-Day Range:
$1.75
$1.80
1-Week Range:
$1.65
$1.9127
52-Week Range:
$1.10
$3.89
Adlai Nortye Ltd Adr Stock (ANL) Company Profile
Compare ANL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANL
Adlai Nortye Ltd Adr
|
1.785 | 65.31M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Adlai Nortye Ltd Adr Stock (ANL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-04-24 | Initiated | H.C. Wainwright | Buy |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
Adlai Nortye Ltd Adr Stock (ANL) Latest News
Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Sees Large Decrease in Short Interest - Defense World
Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Sees Large Increase in Short Interest - MarketBeat
What machine learning models say about Adlai Nortye Ltd. Depositary ReceiptTrade Performance Summary & Verified Chart Pattern Trade Signals - Newser
Using portfolio simulators with Novo Nordisk A s (b Shares) Adrhedged includedJuly 2025 Selloffs & Trade Opportunity Analysis Reports - Newser
Live market analysis of SPAIJuly 2025 Intraday Action & AI Forecasted Entry and Exit Points - Newser
Key resistance and support levels for Adlai Nortye Ltd. Depositary ReceiptJuly 2025 Final Week & Fast Gain Stock Tips - Newser
Candlestick signals on FBGL stock todayForecast Cut & Stock Market Timing Techniques - Newser
F.N.B. Corporation stock trendline breakdownJuly 2025 Decliners & Fast Exit and Entry Strategy Plans - Newser
Is Brookfield Asset Management Ltd. stock reversal real or fake2025 Price Action Summary & Reliable Price Breakout Alerts - Newser
How to use a screener to detect IROHW breakouts2025 Risk Factors & Expert Curated Trade Setups - Newser
Analyzing drawdowns of Coeptis Therapeutics Holdings Inc. with statistical toolsTrade Exit Summary & Real-Time Market Sentiment Reports - Newser
Is GSK plc ADRhedged forming a bottoming base2025 Biggest Moves & Precise Entry and Exit Recommendations - Newser
Trend analysis for Intercontinental Exchange Inc. this weekWeekly Risk Report & Reliable Intraday Trade Alerts - Newser
Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Sees Significant Increase in Short Interest - Defense World
Bank of Nova Scotia (The) (NYSE:BNS) Receives $81.00 Average Target Price from Brokerages - Defense World
Long term hold vs stop loss in CEADJuly 2025 PostEarnings & Reliable Price Breakout Alerts - Newser
Adlai Nortye (NASDAQ:ANL) Stock Price Up 3.2% – Should You Buy? - Defense World
Analysts Offer Insights on Healthcare Companies: Avalo Therapeutics (AVTX), Iovance Biotherapeutics (IOVA) and NextCure (NXTC) - The Globe and Mail
AlphaTime Acquisition Corp Debt Equity Composite Units recovery potential after sell offFree Long Hold Safe Return Strategy - Newser
Comparing Adlai Nortye Ltd. Depositary Receipt in custom built stock radarsDaily Upside Movement Prediction With Data - Newser
Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (VKTX) and Gilead Sciences (GILD) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Esperion (ESPR) - The Globe and Mail
Adlai Nortye Ltd. Announces 2025 Share Incentive Plan and Board Changes - TipRanks
Analysts Offer Insights on Healthcare Companies: NextCure (NXTC), Lexaria Bioscience (LEXX) and Travere Therapeutics (TVTX) - The Globe and Mail
Adlai Nortye (NASDAQ:ANL) Trading Down 5.5% – Here’s What Happened - Defense World
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Capricor Therapeutics (CAPR) and Abbott Laboratories (ABT) - The Globe and Mail
H.C. WAINWRIGHT CUTS ADLAI NORTYE STOCK RATING AFTER TRIAL RESULTS By Investing.com - Investing.com South Africa
H.C. WAINWRIGHT CUTS ADLAI NORTYE STOCK RATING AFTER TRIAL RESULTS - Investing.com
Adlai Nortye Discontinues Buparlisib Development After Phase III Trial Results - TipRanks
ANL stock touches 52-week low at $1.71 amid sharp annual decline - Investing.com India
ANL stock touches 52-week low at $1.71 amid sharp annual decline By Investing.com - Investing.com South Africa
Adlai Nortye to present at AACR Annual Meeting with two abstracts scheduled. - AInvest
ANL stock touches 52-week low at $1.85 amid sharp annual decline By Investing.com - Investing.com South Africa
ANL stock touches 52-week low at $1.85 amid sharp annual decline - Investing.com India
Adlai Nortye stock hits 52-week low at $1.85 amid sharp decline By Investing.com - Investing.com South Africa
Adlai Nortye stock hits 52-week low at $1.85 amid sharp decline - Investing.com India
Adlai Nortye Announces Change in Auditing Firm - TipRanks
Adlai Nortye stock strengthened by oncology trial results, H.C. Wainwright keeps at Buy list - Investing.com India
Adlai Nortye IPO gives old Novartis cancer drug new life - BioPharma Dive
Adlai Nortye Announces 2.5M ADS IPO at $23/sh - Investing.com
CRVO Stock Quote Price and Forecast - CNN
Adlai Nortye Ltd Adr Stock (ANL) Financials Data
There is no financial data for Adlai Nortye Ltd Adr (ANL). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):